Let me get this straight. The brief spike down on high volume is because of BARDA’s decision to concentrate on funding vaccines vs. respiratory-related treatments? Although overall negative, it’s hard to believe anyone sold a share because of that news! If anyone is invested here because of a potential BARDA award related to Covid-19, he/she seems to be missing the larger point.